9th CAR-TCR Summit Europe – FAQs - 9th CAR-TCR Summit Europe 2026

Find the key details you need to plan your CAR-TCR Summit 2026 experience below, including registration options, event dates, venue and accommodation details, and a snapshot of the experts you'll meet at the world's leading cell therapy conference. If your question isn't answered here, don't hesitate to reach out at info@hansonwade.com, and a member of the team will be happy to help!

What is the focus of the CAR-TCR Summit Europe?

The summit brings together scientific, clinical, manufacturing, regulatory, and commercial leaders driving innovation in CAR-T, TCR-T, allogeneic platforms, in-vivo engineering, and next-generation cell therapies. Sessions highlight new engineering strategies, translational research, clinical progress, and solutions to scale, automate, and commercialise advanced therapies in Europe and beyond.

What differentiates this summit from other cell therapy meetings?

Who typically attends?

What key themes will be addressed this year?

Engineering strategies for improved potency, selectivity, and safety
Overcoming barriers in solid tumour targeting
Allogeneic cell therapy platforms and gene-edited approaches
In-vivo engineering and delivery technologies
Automated and closed manufacturing systems
Analytical development, QC, comparability, and release testing
Clinical trial design and safety management
Commercial readiness and European regulatory considerations

What challenges and opportunities in solid tumour CAR-T/TCR-T development, manufacturing scalability, and European regulatory & commercial strategy will be addressed at the summit?

The summit provides a cross-functional, end-to-end view of the key scientific, manufacturing, and regulatory drivers shaping next-generation cell therapy in Europe. Scientific sessions explore the major R&D and translational challenges in solid tumours, including multi-targeting designs, armoured constructs, trafficking enhancement, durability, resistance to the tumour microenvironment, and lessons learned from early-phase clinical programs.

Manufacturing and CMC-focused discussions examine scale-up and scale-out constraints, vector supply, automation, closed and digitalised manufacturing systems, allogeneic platform efficiencies, and analytical development, QC and comparability strategies required for robust and cost-effective production.

Regulatory and commercial sessions highlight the evolving European ATMP regulatory landscape, including expectations for potency assays, gene-editing considerations, long-term follow-up, comparability, and clinical trial design. These sessions also address pathways to commercial readiness, pricing and reimbursement challenges, and successful launch strategies for CAR-T, TCR-T, and next-generation engineered cell therapies across the EU.